Chikungunya Fever Global Clinical Trials Review, H2, 2018

2018-12-31
Price :
Published : Dec-2018
No. of Pages : 50

Chikungunya Fever Global Clinical Trials Review, H2, 2018

Summary

GlobalData’s clinical trial report, “Chikungunya Fever Global Clinical Trials Review, H2, 2018” provides an overview of Chikungunya Fever clinical trials scenario. This report provides top line data relating to the clinical trials on Chikungunya Fever. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Filed in: Pharmaceutical, Therapeutics
Publisher : GlobalData
More Reports
Title Price Buy Now

Hepatitis B: Competitive Landscape to 2027

Hepatitis B: Competitive Landscape to 2027 Summary Hepatitis B is a viral infection of the liver that can become chronic in young children, especially newborns to mothers with HBV infections, and people with compromised immune systems. Chronic hepatitis B is defined as measurable Hepatitis surface antigen (HBsAg) levels for more than six months after an acute infection. Despite the existence of prophylactic vaccines, hepatitis B remains a global public health threat, with approximately 257 million people worldwide living with chronic HBV infections. Chronic hepatitis B cannot be cured and patients have elevated risks of developing liver cirrhosis and hepatocellular carcinoma (HCC). This report provides an assessment of the pipeline, clinical, and commercial landscape of Hepatitis B. Ov......
$3495

Pediatric Vaccines: Epidemiology Forecast to 2028

Pediatric Vaccines: Epidemiology Forecast to 2028 Summary The administration of a vaccine, referred to as vaccination, elicits an immune response that prevents an individual from developing a specific disease when exposed to the corresponding infectious agent in the future. A successful vaccination results in immunization, where the individual is deemed immune to the disease. Routine immunization programs aim to protect children at an early age, when they are the most vulnerable to disease. Prior to the discovery of vaccines, several infectious diseases claimed the lives of millions of children each year. GlobalData epidemiologists utilized comprehensive, country-specific vaccination rate data from nationally representative public health surveillance systems and databases to arrive at ......
$3995

Parkinson’s Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects

Parkinson's Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects Summary Parkinson's disease (PD), a progressive neurological disorder that affects movement control, is associated with considerable quality of life impairments and burden of care, particularly in the advanced disease stages. Cognitive and behavioral complications of PD are common. PD-associated dementia and PD-associated psychosis are both highly prevalent and associated with a large disease burden. There is a pressing unmet need within PD, PD-associated dementia, and PD-associated psychosis for more effective disease-modifying pharmacotherapies. Although current therapies can provide patients with symptomatic relie......
$6995

Obesity: Gut Hormone Receptors Retain Commercial Prominence

Obesity: Gut Hormone Receptors Retain Commercial Prominence Summary Obesity is a chronic and potentially fatal disease. The most prevalent metabolic disorder affecting people today, obesity requires multidisciplinary continuing treatment. Despite the market's clinical and regulatory challenges, the obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, which is in line with its multifactorial etiology. The primary concern within the market is the need for medications that adequately address the unmet clinical needs in the overweight and obese population, namely efficacious and safe therapies. This report assesses first-in-class innovation across the obesity pipeline. Scope - The obesity pipeline is robust and contains a high leve......
$6995

Ulcerative Colitis: Epidemiology Forecast to 2026 – Update

Ulcerative Colitis: Epidemiology Forecast to 2026 - Update Summary Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by long-lasting inflammation and ulcers (sores) in the lining of the colon. UC is limited to the colon and has less frequent complications. GlobalData's epidemiological forecast for the diagnosed incidence, diagnosed prevalence, undiagnosed prevalence, and total prevalence of UC in the 7MM is supported by nationally representative, country-specific studies published in peer-reviewed journals of national healthcare databases and registries. In addition, to improve the comparability of the forecast diagnosed incident and diagnosed prevalent cases of UC across markets, GlobalData epidemiologists used sources that provided uniform diagnostic criteri......
$3995

Pain: GPCR and Nerve Growth Factor-Based Therapies Offer Strong Potential in Difficult-to-Treat Subtypes

Pain: GPCR and Nerve Growth Factor-Based Therapies Offer Strong Potential in Difficult-to-Treat Subtypes Summary The pain therapeutics market has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established active pharmaceutical ingredients and mechanisms of action. The moderate-to-severe pain space continues to be dominated by opioids, which are increasingly being reformulated to offer abuse resistance, whereas mild pain is effectively treated with non-steroidal anti-inflammatory drugs (NSAIDs). However, significant unmet needs remain, as chronic pain subtypes-particularly neuropathic pain-do not respond well to existing therapies. This report assesses first-in-class innovation across the pai......
$6995

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2018

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2018 Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2018", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q4 2018. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides informati......
$1500

Partnerships, Licensing, Investments and M&A Deals and Trends for January 2019 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for January 2019 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for January 2019 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in January 2019. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report pr......
$1000

Asthma and Chronic Obstructive Pulmonary Disease: Asthma Ahead of COPD in Terms of Innovation with the Focus on Targeted Biologic Therapies for Severe Disease Phenotypes

Asthma and Chronic Obstructive Pulmonary Disease: Asthma Ahead of COPD in Terms of Innovation with the Focus on Targeted Biologic Therapies for Severe Disease Phenotypes Summary Asthma and COPD are both highly prevalent, chronic, inflammatory diseases of the airways and lungs. The asthma market is highly saturated with relatively efficacious standard therapies and the COPD market is also highly saturated with therapies that help to prevent exacerbations of the disease. However, there is considerable unmet need for innovative new therapies for severe asthmatics who do not respond to the current standards of care, and treatments which can reverse the progression of COPD. This report assesses first-in-class innovation across the asthma and COPD pipelines. Scope - Both the asthma and COPD ......
$6995

Partnerships, Licensing, Investments and M&A Deals and Trends for February 2019 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for February 2019 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for February 2019 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in February 2019. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report......
$1000
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy